BioLASCO Taiwan (6662) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 樂斯科

BioLASCO Taiwan (6662) reported revenue of NT$19.5 million for Oct 2026, +6.7% year on year and -8.4% from the previous month. Revenue for Jan–Oct 2026 was NT$216.8 million (+2.4% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 126 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$25.8 million24/10Nov 2024 NT$23.1 millionDec 2024 NT$34.8 millionJan 2025 NT$19.8 millionFeb 2025 NT$19.6 million25/02Mar 2025 NT$20.4 millionApr 2025 NT$24.5 millionMay 2025 NT$23.9 millionJun 2025 NT$21.8 million25/06Jul 2025 NT$22.2 millionAug 2025 NT$20.1 millionSep 2025 NT$21 millionOct 2025 NT$18.3 million25/10Nov 2025 NT$21.6 millionDec 2025 NT$29.4 millionJan 2026 NT$24.5 millionFeb 2026 NT$10.4 million26/02Mar 2026 NT$26.2 millionApr 2026 NT$22.3 millionMay 2026 NT$19.3 millionJun 2026 NT$22.9 million26/06Jul 2026 NT$23.8 millionAug 2026 NT$26.7 millionSep 2026 NT$21.3 millionOct 2026 NT$19.5 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$19.5 million+6.7%-8.4%
Sep 2026NT$21.3 million+1.5%-20.2%
Aug 2026NT$26.7 million+32.8%+12.2%
Jul 2026NT$23.8 million+7.3%+3.6%
Jun 2026NT$22.9 million+5.3%+18.9%
May 2026NT$19.3 million-19.4%-13.3%
Apr 2026NT$22.3 million-9.3%-15.0%
Mar 2026NT$26.2 million+28.1%+152.4%
Feb 2026NT$10.4 million-47.1%-57.6%
Jan 2026NT$24.5 million+23.4%-16.9%
Dec 2025NT$29.4 million-15.4%+36.6%
Nov 2025NT$21.6 million-6.7%+17.9%
Oct 2025NT$18.3 million-29.2%-12.8%
Sep 2025NT$21 million+2.9%+4.5%
Aug 2025NT$20.1 million-28.9%-9.4%
Jul 2025NT$22.2 million+10.1%+1.7%
Jun 2025NT$21.8 million-54.2%-9.0%
May 2025NT$23.9 million+0.1%-2.4%
Apr 2025NT$24.5 million+18.0%+20.1%
Mar 2025NT$20.4 million+22.0%+4.2%
Feb 2025NT$19.6 million+30.0%-1.1%
Jan 2025NT$19.8 million+24.9%-43.1%
Dec 2024NT$34.8 million-1.8%+50.6%
Nov 2024NT$23.1 million-5.4%-10.4%
Oct 2024NT$25.8 million+17.3%+26.7%

Jan–Oct 2026 cumulative: NT$216.8 million (+2.4% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: BioLASCO Taiwan vs PEC / BioLASCO Taiwan vs Lotus Pharm / BioLASCO Taiwan vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16